Lupin Limited (Biotech Division) – FDA CRL

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lupin Limited (Biotech Division) regarding its Biologics License Application (BLA 761212) for LUBT004. The agency has determined that the application cannot be approved in its present form due to several outstanding deficiencies.

A key issue involves unresolved deficiencies identified during a pre-license inspection of a manufacturing facility. Lupin is required to provide the date of the facility's response to the FDA Form 483 and ensure these issues are addressed, which may necessitate a re-inspection.

Furthermore, the FDA mandates a comprehensive safety update. This update must detail any significant changes in the product's safety profile, compare new clinical study data with original BLA data, and provide combined tabulations of adverse events and study discontinuations. It also requires updated exposure information, a summary of worldwide safety experience, and English translations of any currently approved foreign labeling. Comments on the proposed prescribing information, carton, and container labeling are reserved until other application issues are adequately addressed, and the conditionally acceptable proprietary name requires resubmission after all deficiencies are resolved.

Under the regulatory framework of 21 CFR 601.3(b), Lupin must fully address all identified deficiencies and resubmit the BLA within one year, or risk the application's withdrawal. The company may also request a meeting with the FDA to discuss the necessary steps for approval.